Physician profile
Dan Pham
NPI 1518313659
$27,905.70
in general payments reported to CMS, 2019-2025
33 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $145 · 2023: $5,048 · 2024: $8,840 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $13K · Travel and Lodging: $266 · Education: $90.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,350.00 |
| Food and Beverage | $13,054.85 |
| Travel and Lodging | $265.75 |
| Education | $90.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $11,324.47 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $7,600.43 | 2023-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $1,325.57 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $984.37 | 2023-2025 | Vemlidy |
| Bayer Healthcare Pharmaceuticals INC. | $749.21 | 2023-2025 | |
| Pfizer INC. | $724.29 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $593.62 | 2024-2025 | Gemtesa, Myfembree |
| Astellas Pharma US INC | $540.95 | 2023-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $515.20 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $456.40 | 2023-2025 | |
| Verona Pharma, INC. | $406.77 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.05 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $219.90 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Baxter Healthcare | $213.14 | 2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Viiv Healthcare Company | $191.30 | 2024 | Apretude |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $190.31 | 2024-2025 | Euflexxa |
| Tempus Ai, INC | $184.69 | 2024-2025 | Xt Cdx |
| Shield Therapeutics INC | $173.23 | 2024-2025 | |
| Exact Sciences Corporation | $157.72 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $148.74 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Viatris Specialty LLC | $127.09 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.16 | 2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $114.29 | 2025 | Zoryve |
| Hologic Sales and Service, LLC | $109.71 | 2023-2025 | Aptima |
| Agios Pharmaceuticals, INC. | $69.22 | 2024-2025 | Pyrukynd |
| Rgh Enterprises LLC | $52.18 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $48.16 | 2025 | |
| Phadia US INC. | $42.38 | 2024-2025 | Immunocap |
| Organon LLC | $30.16 | 2025 | Nexplanon |
| Mylan Specialty L.P. | $29.95 | 2024 | Yupelri |
| Dexcom, INC. | $24.53 | 2024 | Dexcom G6 Transmitter |
| Scilex Pharmaceuticals INC. | $23.84 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $20.67 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.